Have a personal or library account? Click to login
Platinum derivatives: generic brands vs. original, in vitro tests Cover

Platinum derivatives: generic brands vs. original, in vitro tests

Revista Romana de Medicina de Laborator
Volume 23 (2015): Issue 4 (December 2015)
By: Sînziana Cetean,  Călin Căinap,  Olga Soriţău,  Corina Tatomir,  Piroska Virag,  Adriana Hangan,  Luminiţa Oprean and  Radu Oprean  
Open Access
|Dec 2015

References

  1. 1. Bertini I, editor. Bioinorganic chemistry. Mill Valley, Calif: University Science Books; 1994. 611 p.
    Search in Google Scholar
  2. 2. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010;39(35):8113. DOI: 10.1039/c0dt00292e10.1039/c0dt00292e
    Search in Google Scholar
  3. 3. Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15(1):1. DOI: 10.1186/2050-6511-15-110.1186/2050-6511-15-1
    Search in Google Scholar
  4. 4. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002 Jun;42(3):317–25. DOI: 10.1016/S1040-8428(01)00219-010.1016/S1040-8428(01)00219-0
    Search in Google Scholar
  5. 5. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep. 2003 Dec;10(6):1663–82. DOI: 10.3892/or.10.6.166310.3892/or.10.6.1663
    Search in Google Scholar
  6. 6. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000335.jsp&mid=WC-0b01ac0580514d5c.
    Search in Google Scholar
  7. 7. Gallelli L, Mumoli L, Palleria C, Piro B, Russo E, Vasapollo P, et al. Safety and efficacy of generic drugs with respect to brand formulation. J Pharmacol Pharmacother. 2013;4(5):110. DOI: 10.4103/0976-500X.12097210.4103/0976-500X.120972385366224347975
    Search in Google Scholar
  8. 8. Vetchy D, Vetcha M, Rabiskova M, Gryczova E, Bartosikova L. Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Med Kaunas Lith. 2007;43(4):326–31.10.3390/medicina43040040
    Search in Google Scholar
  9. 9. Poirier E, Desbiens C, Poirier B, Hogue J-C, Lemieux J, Doyle C, et al. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Ann Pharmacother. 2014 Apr;48(4):447–55. DOI: 10.1177/106002801351494110.1177/106002801351494124321851
    Search in Google Scholar
  10. 10. Tange M, Yoshida M, Nakai Y, Uchida T. Comparison between original and generic versions of ceftriaxone sodium preparation for injection: compatibility with calcium-containing product. Chem Pharm Bull (Tokyo). 2012;60(4):429–34. DOI: 10.1248/cpb.60.42910.1248/cpb.60.42922466725
    Search in Google Scholar
  11. 11. Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Tazuma S. Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2006 Aug;38(8):554–9. DOI: 10.1016/j.dld.2006.01.03210.1016/j.dld.2006.01.03216524789
    Search in Google Scholar
  12. 12. Minzi OMS, Marealle IA, Shekalaghe S, Juma O, Ngaimisi E, Chemba M, et al. Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product. Malar J. 2013;12:174. DOI: 10.1186/1475-2875-12-17410.1186/1475-2875-12-174366961123718725
    Search in Google Scholar
  13. 13. Gasser UE, Fischer A, Timmermans JP, Arnet I. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®. BMC Pharmacol Toxicol. 2013;14(1):24. DOI: 10.1186/2050-6511-14-2410.1186/2050-6511-14-24364849123617953
    Search in Google Scholar
  14. 14. Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004 [cited 2015 May 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53196/
    Search in Google Scholar
  15. 15. Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N, et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods San Diego Calif. 2013 Jun 1;61(2):117–29. DOI: 10.1016/j.ymeth.2013.02.01110.1016/j.ymeth.2013.02.01123473780
    Search in Google Scholar
  16. 16. Krysko DV, Vanden Berghe T, D’Herde K, Vandenabeele P. Apoptosis and necrosis: Detection, discrimination and phagocytosis. Methods. 2008 Mar;44(3):205–21. DOI: 10.1016/j.ymeth.2007.12.00110.1016/j.ymeth.2007.12.00118314051
    Search in Google Scholar
  17. 17. Chang Y-J, Huang C-Y, Hung C-S, Chen W-Y, Wei P-L. GRP78 mediates the therapeutic efficacy of curcumin on colon cancer. Tumor Biol. 2015 Feb;36(2):633–41. DOI: 10.1007/s13277-014-2640-310.1007/s13277-014-2640-325277658
    Search in Google Scholar
  18. 18. Liou J-Y, Aleksic N, Chen S-F, Han T-J, Shyue S-K, Wu KK. Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res. 2005 May 15;306(1):75–84. DOI: 10.1016/j. yexcr.2005.01.011
    Search in Google Scholar
  19. 19. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M. Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells. Yeudall A, editor. PLoS ONE. 2014 Apr 23;9(4):e94621.10.1371/journal.pone.0094621399740324760019
    Search in Google Scholar
  20. 20. Rasul KI, Kamal AS, Al-Najjar NM, Oculalan MH. Is there a Diference between Brand and Generic Oxaliplatin? Cancer Clin Oncol [Internet]. 2012 Jun 18 [cited 2015 Apr 30];1(2). Available from: http://www.ccsenet.org/journal/index.php/cco/article/view/1815710.5539/cco.v1n2p45
    Search in Google Scholar
  21. 21. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ. 2001 Jun 23;322(7301):1536–8. DOI: 10.1136/bmj.322.7301.153610.1136/bmj.322.7301.1536112057611420279
    Search in Google Scholar
  22. 22. Florea A-M, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 2011 Mar 15;3(4):1351–71. DOI: 10.3390/cancers301135110.3390/cancers3011351375641724212665
    Search in Google Scholar
  23. 23. Henry CM, Hollville E, Martin SJ. Measuring apoptosis by microscopy and flow cytometry. Methods. 2013 Jun;61(2):90–7. DOI: 10.1016/j.ymeth.2013.01.00810.1016/j.ymeth.2013.01.00823403105
    Search in Google Scholar
DOI: https://doi.org/10.1515/rrlm-2015-0043 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 439 - 448
Submitted on: Jun 8, 2015
Accepted on: Sep 24, 2015
Published on: Dec 30, 2015
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Oxaliplatin,
generic vs original,
cancer,
carboplatin
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2015 Sînziana Cetean, Călin Căinap, Olga Soriţău, Corina Tatomir, Piroska Virag, Adriana Hangan, Luminiţa Oprean, Radu Oprean, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 23 (2015): Issue 4 (December 2015)Next article